Advertisement

An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients.

Julie Toplin, Courtney Fuller, Linda Fletcher, Stephane Wong, Peter Maslak, Jorge Cortes, Rosemary Mazanet, Susan Branford, Timothy Hughes, Chad Galderisi, Michael Heinrich, Brian Druker and Emmanuel Beillard

Article Information

Citation 
vol. 110 no. 11 2939

Print ISSN 
Online ISSN 
History 
  • Published online September 8, 2015.


Contributors 
  • Julie Toplin, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Courtney Fuller, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Linda Fletcher, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Stephane Wong, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Peter Maslak, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Jorge Cortes, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Rosemary Mazanet, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Susan Branford, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Timothy Hughes, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Chad Galderisi, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Michael Heinrich, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Brian Druker, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.
  • Emmanuel Beillard, 1MolecularMD, Corp., Portland, OR, USA; 2Division of Molecular Pathology, IMVS, Adelaide, South Australia, Australia; 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Breakthrough Therapeutics, Greenwich, CT, USA; 6Veterans Affairs Medical Center, Portland, OR, USA and 7Oregon Health and Sciences University, Portland, OR, USA.

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output